TrialThe New England journal of medicine2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,078 papers cite itlatest 60 shown
this paperpooled ittrialcites it